A randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of the safety and efficacy of ABT-894 in adults with attention deficit-hyperactivity disorder (ADHD)

Trial Profile

A randomized, double-blind, placebo-controlled, phase 2 dose-ranging study of the safety and efficacy of ABT-894 in adults with attention deficit-hyperactivity disorder (ADHD)

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Feb 2013

At a glance

  • Drugs Sofinicline (Primary) ; Atomoxetine
  • Indications Attention-deficit hyperactivity disorder
  • Focus Therapeutic Use
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 20 Jun 2008 Positive results reported in a NeuroSearch media release.
    • 01 Aug 2007 Primary endpoint 'Conners'-Attention-Deficit-Hyperactivity-Disorder-Rating-Scale' has been met.
    • 08 Mar 2007 Status changed from recruiting to in progress
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top